ASP8825 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathies
Conditions
Diabetic Neuropathies
Trial Timeline
Jul 1, 2007 → Nov 1, 2008
NCT ID
NCT00508430About ASP8825 + Placebo
ASP8825 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Diabetic Neuropathies. The current trial status is terminated. This product is registered under clinical trial identifier NCT00508430. Target conditions include Diabetic Neuropathies.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00530530 | Phase 2 | Completed |
| NCT00508430 | Phase 2 | Terminated |
Competing Products
20 competing products in Diabetic Neuropathies